These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28862172)

  • 21. Prophylactic recombinant hepatitis B vaccine in patients undergoing orthotopic liver transplantation.
    Berner J; Kadian M; Post J; Miller C; Schwartz M; Conn M; Borcich A
    Transplant Proc; 1993 Apr; 25(2):1751-2. PubMed ID: 8470152
    [No Abstract]   [Full Text] [Related]  

  • 22. DNA-based immunization against hepatitis B virus.
    Davis HL; Brazolot Millan CL
    Springer Semin Immunopathol; 1997; 19(2):195-209. PubMed ID: 9406346
    [No Abstract]   [Full Text] [Related]  

  • 23. [Explanation of hepatitis B virus markers after hepatitis B vaccines inoculation].
    Chen H; Zhu QR
    Zhonghua Gan Zang Bing Za Zhi; 2003 Apr; 11(4):240. PubMed ID: 12716528
    [No Abstract]   [Full Text] [Related]  

  • 24. Hepatitis B vaccines.
    Yu AS; Cheung RC; Keeffe EB
    Clin Liver Dis; 2004 May; 8(2):283-300. PubMed ID: 15481341
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hepatitis B vaccines: protective efficacy and therapeutic potential.
    Michel ML; Tiollais P
    Pathol Biol (Paris); 2010 Aug; 58(4):288-95. PubMed ID: 20382485
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impaired response to recombinant hepatitis B vaccine in asymptomatic HIV-infected individuals.
    Tayal SC; Sankar KN
    AIDS; 1994 Apr; 8(4):558-9. PubMed ID: 7912087
    [No Abstract]   [Full Text] [Related]  

  • 27. Candidate mucosal vaccine against hepatitis B based on tomatoes transgenic for the preS2-S gene.
    Salyaev RK; Rekoslavskaya NI; Stolbikov AS; Tret'yakova AV
    Dokl Biochem Biophys; 2012; 446():257-9. PubMed ID: 23132723
    [No Abstract]   [Full Text] [Related]  

  • 28. [The experimental efficacy of vaccination with a recombinant yeast vaccine against hepatitis B in combination with immunomodulators].
    Barinskiĭ IF; Lycheva IA; Suetina IA; Posevaia TA; Granovskiĭ NN
    Vopr Virusol; 1994; 39(1):21-4. PubMed ID: 8160443
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hepatitis B vaccine effectiveness in the face of global HBV genotype diversity.
    Cassidy A; Mossman S; Olivieri A; De Ridder M; Leroux-Roels G
    Expert Rev Vaccines; 2011 Dec; 10(12):1709-15. PubMed ID: 22085174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A boost to hepatitis B vaccine: no need for boosters.
    Aggarwal R
    Natl Med J India; 2005; 18(6):313-4. PubMed ID: 16483032
    [No Abstract]   [Full Text] [Related]  

  • 31. Preadolescent non- and hyporesponders following three doses of hepatitis B vaccine need only one more dose.
    Duval B; Boulianne N; De Serres G; De Wals P; Massé R; Trudeau G
    Vaccine; 2002 Nov; 20(31-32):3632-4. PubMed ID: 12399188
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Persistence of immunity after hepatitis B vaccination].
    Madaliński K
    Przegl Epidemiol; 2002; 56(4):605-13. PubMed ID: 12666586
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatitis B Virus Revaccination With Standard Versus Pre-S Vaccine in Previously Immunized Patients With Celiac Disease.
    Heshin-Bekenstein M; Turner D; Shamir R; Bar-Meir M; Dagan R; Zevit N; Silbermintz A
    J Pediatr Gastroenterol Nutr; 2015 Oct; 61(4):400-3. PubMed ID: 25988560
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The recombinant hepatitis B surface antigen vaccine in persons with HIV: is seroconversion sufficient for long-term protection?
    Powis JE; Raboud J; Ostrowski M; Loutfy MR; Kovacs C; Walmsley SL
    J Infect Dis; 2012 May; 205(10):1534-8. PubMed ID: 22448009
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults.
    Knöll A; Hottenträger B; Kainz J; Bretschneider B; Jilg W
    Vaccine; 2000 Apr; 18(19):2029-32. PubMed ID: 10706965
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Antibodies against hepatitis B after vaccination in health workers].
    Pérez-López JA; García-Elorriaga G; Del Rey-Pineda G; Manjarrez-Téllez B
    Salud Publica Mex; 2011; 53(3):205-6. PubMed ID: 21829884
    [No Abstract]   [Full Text] [Related]  

  • 37. MF59 adjuvant enhances the antibody response to recombinant hepatitis B surface antigen vaccine in primates.
    Traquina P; Morandi M; Contorni M; Van Nest G
    J Infect Dis; 1996 Dec; 174(6):1168-75. PubMed ID: 8940205
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Maintenance of immune memory to the hepatitis B envelope protein following adoptive transfer of immunity in bone marrow transplant recipients.
    Ilan Y; Nagler A; Zeira E; Adler R; Slavin S; Shouval D
    Bone Marrow Transplant; 2000 Sep; 26(6):633-8. PubMed ID: 11035369
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immune persistence 17 to 20 years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination.
    Zhao YL; Han BH; Zhang XJ; Pan LL; Zhou HS; Gao Z; Hao ZY; Wu ZW; Ma TL; Wang F; Li Q; Bi SL; Ma JC
    BMC Infect Dis; 2019 May; 19(1):482. PubMed ID: 31146699
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of three different recombinant hepatitis B vaccines: GeneVac-B, Engerix B and Shanvac B in high risk infants born to HBsAg positive mothers in India.
    Velu V; Nandakumar S; Shanmugam S; Jadhav SS; Kulkarni PS; Thyagarajan SP
    World J Gastroenterol; 2007 Jun; 13(22):3084-9. PubMed ID: 17589924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.